Christopher Waddick
Direttore Finanziario/CFO presso CARDIOL THERAPEUTICS INC.
Patrimonio netto: 202 400 $ in data 30/04/2024
Posizioni attive di Christopher Waddick
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CARDIOL THERAPEUTICS INC. | Direttore/Membro del Consiglio | 19/05/2022 | - |
| Direttore Finanziario/CFO | 16/08/2018 | - | |
| Segretario Aziendale | 16/08/2018 | - | |
Active Energy, Inc.
 Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Direttore Finanziario/CFO | 01/01/2013 | - |
| Presidente | 01/01/2013 | - | |
| Nrj Consulting, Inc. | Presidente | 01/11/2009 | - |
Storia della carriera di Christopher Waddick
Precedenti posizioni note di Christopher Waddick
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Amministratore Delegato | - | - |
| Direttore operativo | 01/07/2005 | 01/06/2007 | |
| Direttore Finanziario/CFO | 01/06/2007 | 23/10/2009 |
Formazione di Christopher Waddick
| York University | Masters Business Admin |
| Wilfrid Laurier University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Canada | 6 |
| Stati Uniti | 2 |
Posizioni
| Director of Finance/CFO | 3 |
| President | 2 |
| Chief Executive Officer | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
| Utilities | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Utilities |
| Nrj Consulting, Inc. |
- Borsa valori
- Insiders
- Christopher Waddick
- Esperienza
